Biodel to Present New Preclinical Glucagon Data During Corporate Overview at JMP Securities Healthcare Conference DANBURY, Conn., July 3, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) announced today that management will present new preclinical pharmacokinetic and pharmacodynamic data on its glucagon formulation intended for use in a novel auto-reconstitution device. Biodel's glucagon injection system is designed to improve on existing treatments for severe hypoglycemia. These data will be presented during a corporate overview of the Company on Tuesday, July 9, 2013 at 12:30 p.m. EDT at the Eighth Annual JMP Securities Healthcare Conference in New York City. A live and archived webcast of the presentation will be accessible on the Biodel website at www.biodel.com under "Webcasts" in the "News & Events" section. About Biodel Inc. Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that may be safer, more effective and more convenient for patients. We develop our product candidates by applying our proprietary formulation technologies to existing drugs in order to improve their therapeutic profiles. More information about Biodel is available at www.biodel.com. BIOD-G CONTACT: Seth D. Lewis, +1-646-378-2952
Biodel to Present New Preclinical Glucagon Data During Corporate Overview at JMP Securities Healthcare Conference
Press spacebar to pause and continue. Press esc to stop.